MetaCap

argenx (ARGX) vs Moderna (MRNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Moderna (MRNA) has outperformed argenx (ARGX) over the past year, gaining 722.1% versus a gain of 0.7%. Over five years, ARGX leads with a +235.3% price change compared with -40.8% for MRNA. Moderna is the larger company by market cap ($78.90 billion vs $58.21 billion), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARGX+0.74%MRNA+722.09%
+1087%+503%-81%
Nov 21, 20251 yearNov 20, 2026
ARGX+225.99%MRNA-26.07%
+284%+88%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARGX versus MRNA key metrics
MetricARGXMRNA
Share price$925.70$195.00
Market cap$58.21B$78.90B
1-day change-1.73%-2.17%
YTD return+10.08%+561.24%
1-year return+0.74%+722.09%
5-year return+235.28%-40.84%
P/E ratio (TTM)32.06—
Forward P/E27.79—
EPS (TTM)$28.87$-7.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.94B
Revenue growth (YoY)—-39.93%
Net income (latest FY)$1.29B$-2.82B
Gross margin—55.35%
Operating margin—-158.13%
Net margin—-145.16%
52-week high$1,072.75$280.80
52-week low$661.85$23.55
Distance from 52-week high-13.71%-30.56%
Analyst consensusbuyhold
Avg. price target upside+24.30%-15.22%
Average volume359.65K16.52M
Shares outstanding62.89M404.62M
Employees1,8634,700
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRNA has outperformed ARGX by 721.4 percentage points over the past year.

About argenx

ARGX stock →

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees

About Moderna

MRNA stock →

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees

ARGX vs MRNA FAQ

Which is bigger, argenx or Moderna?

Moderna (MRNA) is larger, with a market capitalization of $78.90B compared with $58.21B for argenx (ARGX).

Which stock has performed better over the past year, ARGX or MRNA?

MRNA returned +722.09% over the past 12 months, compared with +0.74% for ARGX (price return, excluding dividends). Past performance does not predict future results.

Are argenx and Moderna in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons